Market Cap 35.92M
Revenue (ttm) 4.01M
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -672.57%
Debt to Equity Ratio 0.00
Volume 12,300
Avg Vol 72,448
Day's Range N/A - N/A
Shares Out 9.26M
Stochastic %K 20%
Beta -0.67
Analysts Strong Sell
Price Target $22.14

Company Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 744 4400
Address:
20 Park Plaza, Suite 424, Boston, United States
Silver_Bishop
Silver_Bishop Apr. 26 at 7:53 PM
$CRVO Thanks for keeping the optimism going on this board. As soon as we know how they will finance p3, blue skies. Data is fantasic, trial is as optimised as can be. Just tell us where the money is coming from!
1 · Reply
BPler
BPler Apr. 26 at 6:41 PM
$CRVO Canaccord Genuity also confirmed BUY with 27 USD leading concluding to: Currently, the analyst consensus on CervoMed is a Strong Buy with an average price target of $20.80, representing a 425.3% upside. In a report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $11.00 price target. (Source: https://www.tipranks.com/stocks/crvo?ref=MCO_STOCK&utm_source=theglobeandmail.com&utm_medium=referral)
0 · Reply
Doki0926
Doki0926 Apr. 24 at 2:26 PM
$CRVO this stock is a tragedy
0 · Reply
BPler
BPler Apr. 24 at 1:39 PM
$CRVO also this week 31 USD PT confirmed, failing to gap up for months on good news. Hopefully there will be a breakout soon https://www.gurufocus.com/news/8810244/crvo-maintained-by-d-boral-capital-price-target-steady-at-31?mobile=true
0 · Reply
BPler
BPler Apr. 24 at 1:36 PM
$CRVO Just for the sake of it, PT still 25 with BUY reiterated https://www.gurufocus.com/news/8812254/crvo-reiterated-by-hc-wainwright-co-price-target-maintained-at-25?mobile=true
0 · Reply
focafoca99
focafoca99 Apr. 23 at 5:45 AM
$CRVO furnished an 8-K attaching Exhibit 99.1 and related corporate materials. https://www.rapidticker.com/news/crvo-sec-filing-a6d39f
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Apr. 23 at 4:41 AM
$CRVO good drugs die without funding, I've seen it too many times. Unfortunately Alan & boger should take the shitty pipe deal and accept 2x, 3x warrant coverage. Dilute themselves down, part of something is better than all of nothing. Probably could of taken it at $10 or $8.X but got greedy and now under $4. I love a come back story, I hope they do it. I have no shares anymore, I usually don't hold for funding but I thought boger would make it happen. Sad days.
1 · Reply
focafoca99
focafoca99 Apr. 22 at 6:40 PM
$CRVO presented AAN 2026 data showing neflamapimod increased basal forebrain volume and functional connectivity in dementia with Lewy bodies. https://www.rapidticker.com/news/crvo-cervomed-announces-new-data-at-c31100
0 · Reply
Ghostofgreg1
Ghostofgreg1 Apr. 22 at 6:40 PM
$CRVO WHAT will it take??? This is BS
1 · Reply
LowCountryHooker
LowCountryHooker Apr. 22 at 12:09 PM
$CRVO Today at the #AANAM, we’re sharing the first-ever MRI analyses from our Phase 2b study of neflamapimod, which suggest that neflamapimod may increase the size and enhance the function of the basal forebrain in patients with dementia with Lewy bodies (DLB). Basal forebrain atrophy is the primary driver of disease expression and progression in DLB. We plan to incorporate this technology into our Phase 3 trial DLB which, subject to financing, we plan to start later this year. You can read more here: https://lnkd.in/eXvF8gPf #DLB #neflamapimod
1 · Reply
Latest News on CRVO
CervoMed Transcript: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 5 weeks ago

CervoMed Transcript: The 38th Annual Roth Conference


CervoMed Transcript: Emerging Growth Conference

Oct 22, 2025, 11:25 AM EDT - 6 months ago

CervoMed Transcript: Emerging Growth Conference


CervoMed to Present at the Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 6 months ago

CervoMed to Present at the Emerging Growth Conference


CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 11:54 AM EDT - 7 months ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial


CervoMed to Participate in Upcoming Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 8 months ago

CervoMed to Participate in Upcoming Investor Conferences


CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 11:20 AM EDT - 9 months ago

CervoMed's Dementia Data Show Slowed Disease Progression


CervoMed Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 9 months ago

CervoMed Transcript: Status Update


CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals


CervoMed Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 3:00 PM EST - 1 year ago

CervoMed Transcript: Stifel 2024 Healthcare Conference


CervoMed Transcript: Status Update

Jul 23, 2024, 10:00 AM EDT - 1 year ago

CervoMed Transcript: Status Update


CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference


CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Appoint William Elder as Chief Financial Officer


CervoMed to Participate in the BIO CEO and Investor Conference

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference


CervoMed to Participate in the Emerging Growth Conference 67

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67


CervoMed to Participate in the Emerging Growth Conference 66

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66


Silver_Bishop
Silver_Bishop Apr. 26 at 7:53 PM
$CRVO Thanks for keeping the optimism going on this board. As soon as we know how they will finance p3, blue skies. Data is fantasic, trial is as optimised as can be. Just tell us where the money is coming from!
1 · Reply
BPler
BPler Apr. 26 at 6:41 PM
$CRVO Canaccord Genuity also confirmed BUY with 27 USD leading concluding to: Currently, the analyst consensus on CervoMed is a Strong Buy with an average price target of $20.80, representing a 425.3% upside. In a report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $11.00 price target. (Source: https://www.tipranks.com/stocks/crvo?ref=MCO_STOCK&utm_source=theglobeandmail.com&utm_medium=referral)
0 · Reply
Doki0926
Doki0926 Apr. 24 at 2:26 PM
$CRVO this stock is a tragedy
0 · Reply
BPler
BPler Apr. 24 at 1:39 PM
$CRVO also this week 31 USD PT confirmed, failing to gap up for months on good news. Hopefully there will be a breakout soon https://www.gurufocus.com/news/8810244/crvo-maintained-by-d-boral-capital-price-target-steady-at-31?mobile=true
0 · Reply
BPler
BPler Apr. 24 at 1:36 PM
$CRVO Just for the sake of it, PT still 25 with BUY reiterated https://www.gurufocus.com/news/8812254/crvo-reiterated-by-hc-wainwright-co-price-target-maintained-at-25?mobile=true
0 · Reply
focafoca99
focafoca99 Apr. 23 at 5:45 AM
$CRVO furnished an 8-K attaching Exhibit 99.1 and related corporate materials. https://www.rapidticker.com/news/crvo-sec-filing-a6d39f
0 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Apr. 23 at 4:41 AM
$CRVO good drugs die without funding, I've seen it too many times. Unfortunately Alan & boger should take the shitty pipe deal and accept 2x, 3x warrant coverage. Dilute themselves down, part of something is better than all of nothing. Probably could of taken it at $10 or $8.X but got greedy and now under $4. I love a come back story, I hope they do it. I have no shares anymore, I usually don't hold for funding but I thought boger would make it happen. Sad days.
1 · Reply
focafoca99
focafoca99 Apr. 22 at 6:40 PM
$CRVO presented AAN 2026 data showing neflamapimod increased basal forebrain volume and functional connectivity in dementia with Lewy bodies. https://www.rapidticker.com/news/crvo-cervomed-announces-new-data-at-c31100
0 · Reply
Ghostofgreg1
Ghostofgreg1 Apr. 22 at 6:40 PM
$CRVO WHAT will it take??? This is BS
1 · Reply
LowCountryHooker
LowCountryHooker Apr. 22 at 12:09 PM
$CRVO Today at the #AANAM, we’re sharing the first-ever MRI analyses from our Phase 2b study of neflamapimod, which suggest that neflamapimod may increase the size and enhance the function of the basal forebrain in patients with dementia with Lewy bodies (DLB). Basal forebrain atrophy is the primary driver of disease expression and progression in DLB. We plan to incorporate this technology into our Phase 3 trial DLB which, subject to financing, we plan to start later this year. You can read more here: https://lnkd.in/eXvF8gPf #DLB #neflamapimod
1 · Reply
BPler
BPler Apr. 22 at 11:45 AM
$CRVO For those who don't follow the science in detail: The data presented on April 22, 2026, at the AAN Annual Meeting is being hailed as a major breakthrough because it represents the first time a therapeutic candidate has demonstrated the potential to reverse brain atrophy in patients with Dementia with Lewy Bodies (DLB).
2 · Reply
BPler
BPler Apr. 22 at 11:40 AM
$CRVO Jumped to 4.35 USD in Trading212 pre-market Phase-2a data for CervoMed's neflamapimod in dementia with Lewy bodies (LBD) showed significant increases in basal forebrain volume and improved functional connectivity, suggesting potential regeneration of damaged neural networks [1]. By specifically targeting the cholinergic degeneration mechanism, these results provide a strong foundation for the upcoming Phase 3 trial, with the strongest effects observed in patients without concomitant Alzheimer’s pathology https://www.globenewswire.com/news-release/2026/04/22/3278843/0/en/CervoMed-Announces-New-Data-at-the-2026-AAN-Annual-Meeting-that-Demonstrated-Neflamapimod-Increased-Basal-Forebrain-Volume-and-Functional-Connectivity-in-Dementia-with-Lewy-Bodies.html
0 · Reply
Nochtar
Nochtar Apr. 21 at 3:25 PM
$CRVO wasteland
1 · Reply
Ghostofgreg1
Ghostofgreg1 Apr. 20 at 2:46 PM
$CRVO Am I seeing a bid size of 10000 against an ask size of 100? Hmmmmmm Maybe………
1 · Reply
Disinformation_Consumer
Disinformation_Consumer Apr. 17 at 8:08 PM
$CRVO If a stock falls at the beginning of a taco event and doesnt rise back up at the end, thats a sign that the stock is basically dead.
0 · Reply
5layer
5layer Apr. 17 at 5:03 PM
0 · Reply
Slimben
Slimben Apr. 16 at 10:22 PM
$CRVO check out that 25,000 share wall at 4.36. I guess we’ll see if that’s a real wall or an iceberg By tomorrow. If it breaks, this thing is gonna take off. If not. Look out below.
1 · Reply
Stu_padasso
Stu_padasso Apr. 14 at 6:28 PM
$CRVO anyone left here would like to have an earnest discussion re path forward with anyone interested
2 · Reply
LowCountryHooker
LowCountryHooker Apr. 9 at 12:28 PM
$CRVO Earlier this week, our CEO Dr. John Alam participated on a panel at the Lewy Body Dementia Association annual meeting with other industry leaders discussing the use of biomarkers in detecting and monitoring dementia with Lewy bodies (#DLB). He pointed out the need for distinct blood and imaging biomarkers to identify and assess DLB relative to other dementias, including Alzheimer’s disease, as DLB is uniquely driven by synaptic dysfunction. We’ve explored the use of relevant biomarkers, such as glial fibrillary acidic protein (GFAP) and plasma pTau181, in our prior clinical trials of neflamapimod, and will build on what we’ve learned in our planned Phase 3 trial, which will start later this year. #Biomarkers #neflamapimod #LBDA
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 8 at 2:46 PM
$CRVO scoundrels…… repeat …..$CRDF too
2 · Reply
Doki0926
Doki0926 Apr. 8 at 1:54 PM
$CRVO 😂😂😂😂😂😂😂😂😂😂🤣🤣🤣🤣🤣🤣🤣🤣🤣
0 · Reply
Doki0926
Doki0926 Apr. 8 at 1:38 PM
$CRVO I think everyone should sell all of their cervo stocks, and fuck this shit company and management
1 · Reply